SAN DIEGO, Oct. 10, 2017 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the 2017 BIO Investor Forum on Wednesday, October 18, 2017, at 9:00 a.m. Pacific Time. The conference will be held at The Westin St. Francis Hotel in San Francisco, CA. Mr. Pascoe will provide an update on the Company’s strategy and plans surrounding Vitaros™.
A live audio webcast of the presentation can be accessed via the Investor Relations’ section of the Company’s website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 30 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Matthew Beck
[email protected]
The Trout Group
(646) 378-2933


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Instagram Outage Disrupts Thousands of U.S. Users
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



